Cystic fibrosis (CF) is a life-limiting genetic disorder that primarily affects the lungs and digestive system, but its reach extends far beyond. Among the most consequential complications is cystic fibrosis-related diabetes (CFRD), a distinct form of diabetes that shares features of both type 1 and type 2 diabetes. CFRD develops in up to 50% of adults with CF and is associated with worse lung function, poorer nutritional status, and increased mortality. For decades, researchers focused on pancreatic damage as the primary driver, but a growing body of evidence points to another key player: the gut microbiota. The community of trillions of microorganisms living in the intestines appears to influence inflammation, metabolism, and insulin regulation in CF. Understanding this connection could open new therapeutic avenues for managing CFRD and improving patient outcomes.

Cystic Fibrosis and Its Metabolic Complications

Cystic fibrosis results from mutations in the CFTR gene, which encodes a chloride channel responsible for regulating fluid and electrolyte transport across epithelial surfaces. Defective CFTR leads to thick, sticky mucus in multiple organs, causing chronic lung infections, pancreatic insufficiency, and intestinal obstruction. Over the past three decades, advances in pulmonary care and nutrition have dramatically extended life expectancy, but this longevity has unmasked a new challenge: CFRD.

CFRD develops when the endocrine pancreas — specifically the islets of Langerhans — suffers progressive damage from fibrosis, fatty infiltration, and inflammation. Unlike classic type 1 diabetes, there is no autoimmune destruction of beta cells. And unlike type 2 diabetes, insulin resistance is less prominent initially, though it often appears during acute illness or with glucocorticoid use. The disease is characterized by delayed and insufficient insulin secretion, combined with varying degrees of insulin resistance. Because CF patients already have an elevated energy expenditure due to chronic infection and malabsorption, the catabolic state of uncontrolled diabetes — with protein breakdown and hyperglycemia — directly worsens lung function and nutritional status. Managing CFRD is thus a critical component of CF care.

Yet the pancreas may not be the only source of endocrine dysfunction. Recent research has highlighted the gut as an important modulator of glucose metabolism, and emerging data suggest that alterations in the gut microbiota — a state of dysbiosis — play a causal or contributory role in the pathogenesis and progression of CFRD.

The Gut Microbiota: A Key Player in Health and Disease

The gut microbiota is the collection of bacteria, archaea, viruses, fungi, and protozoa that colonize the gastrointestinal tract. The vast majority reside in the colon, where they reach densities of 1011–1012 cells per gram of luminal content. Although the composition varies between individuals, certain phyla — Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia — dominate. These microorganisms perform essential functions: they ferment undigested dietary fibers into short-chain fatty acids (SCFAs), such as butyrate, acetate, and propionate; they synthesize vitamins (e.g., vitamin K, B12); they regulate host immune responses; and they influence energy homeostasis and glucose metabolism.

The composition of the gut microbiota is shaped early in life by mode of delivery, diet, antibiotic exposure, and genetics, and it remains relatively stable in adulthood barring major perturbations. A diverse and balanced microbial community is considered a hallmark of good health. In contrast, dysbiosis — a state of reduced diversity, loss of beneficial microbes, and overgrowth of potentially pathogenic organisms — has been linked to numerous diseases, including obesity, type 2 diabetes, inflammatory bowel disease, and colorectal cancer. The mechanisms by which the gut microbiome affects host metabolism include modulation of host gene expression, regulation of intestinal permeability, production of metabolites that act as signaling molecules, and cross-talk with the immune system.

Gut Microbiota Alterations in Cystic Fibrosis

Patients with cystic fibrosis exhibit profound alterations in their gut microbiota from a very young age. Several factors contribute to this dysbiosis: repeated antibiotic courses for lung infections, impaired bile acid secretion due to CFTR dysfunction, intestinal inflammation, and pancreatic insufficiency with malabsorption. The result is a gut microbial community that is markedly different from that of healthy controls.

Reduced Diversity

Multiple studies have shown that CF patients have significantly lower alpha diversity — a measure of the number and abundance of species — in their fecal microbiota compared to healthy individuals. Reduced diversity is consistently associated with poorer health outcomes, including increased inflammation and a higher risk of chronic disease. In CF, low diversity correlates with more frequent pulmonary exacerbations and worse nutritional status.

Altered Composition

At the phylum level, CF patients often exhibit a decrease in Firmicutes and an increase in Proteobacteria, which includes many opportunistic pathogens. Beneficial bacteria such as Faecalibacterium prausnitzii — a major butyrate producer known for its anti-inflammatory properties — are consistently depleted. Bacteroides species, which help degrade complex carbohydrates and contribute to metabolic health, are also reduced. Meanwhile, potentially pathogenic genera like Escherichia, Klebsiella, and Pseudomonas are more abundant. These changes are not passive; they actively contribute to a pro-inflammatory environment in the gut and beyond.

Increased Intestinal Inflammation

The dysbiotic gut in CF is characterized by elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-8. The loss of butyrate-producing bacteria is particularly detrimental, because butyrate is the primary fuel for colonocytes and has potent anti-inflammatory effects. Butyrate also reinforces the intestinal epithelial barrier; low levels can lead to increased intestinal permeability, or “leaky gut,” allowing bacterial products such as lipopolysaccharide (LPS) to translocate into the bloodstream and trigger systemic inflammation. This systemic inflammation may contribute to insulin resistance and beta-cell dysfunction, both of which are central to CFRD pathogenesis.

Mechanisms Connecting Gut Dysbiosis to CFRD

The link between gut microbiota dysbiosis and CFRD is still being dissected, but several plausible mechanisms have emerged from preclinical and clinical studies.

Short-Chain Fatty Acids and Insulin Sensitivity

SCFAs, particularly butyrate, acetate, and propionate, are produced by bacterial fermentation of dietary fiber. They are absorbed into the circulation and act on host tissues via specific G-protein-coupled receptors (GPR41, GPR43) and by inhibiting histone deacetylases. Butyrate has been shown to improve insulin sensitivity, reduce inflammation, and enhance pancreatic beta-cell function in animal models. In CF, the depletion of butyrate-producing bacteria likely reduces SCFA levels, thereby diminishing these protective effects. A study by Flass et al. (2020) found that CF patients with lower fecal butyrate had higher markers of systemic inflammation and poorer glucose tolerance. Restoring SCFA production through diet or microbial therapy is a promising strategy.

Bile Acid Metabolism

Bile acids, synthesized in the liver and modified by the gut microbiota, are critical regulators of glucose and lipid metabolism. In CF, defective CFTR impairs bile acid secretion and enterohepatic circulation, leading to a higher proportion of primary bile acids and reduced bacterial transformation to secondary bile acids. Secondary bile acids such as deoxycholic acid and lithocholic acid have been shown to activate the nuclear receptor FXR (farnesoid X receptor) and the TGR5 receptor, both of which influence insulin secretion and energy expenditure. An altered bile acid profile in CF may contribute to metabolic dysregulation and the development of CFRD.

Intestinal Permeability and Endotoxemia

Increased intestinal permeability is a hallmark of CF-related gut disease. The loss of tight junction integrity, partly due to low butyrate and high inflammation, allows bacterial endotoxin (LPS) to enter the portal circulation. LPS activates toll-like receptor 4 (TLR4) on immune cells and adipocytes, triggering a cascade of pro-inflammatory cytokines and promoting insulin resistance. Studies in non-CF populations have established a strong link between endotoxemia and type 2 diabetes; emerging evidence suggests a similar role in CFRD. For example, a 2021 study by Fridge et al. found that CF patients with CFRD had significantly higher plasma LPS levels than those without diabetes, and LPS levels correlated with reduced insulin secretion.

Gut-Brain-Pancreas Axis

Gut microbes can influence glucose metabolism through the enteric nervous system and through direct effects on incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Butyrate and other microbial metabolites stimulate L-cells in the gut to secrete GLP-1, which enhances insulin secretion and promotes beta-cell survival. In CF, reduced SCFA production may blunt GLP-1 release, contributing to the defective insulin secretion seen in CFRD. Additionally, the dysbiotic gut may produce metabolites that interfere with neural signaling, further disinhibiting pancreatic insulin release.

Immune Dysregulation

The gut microbiota is a master regulator of both local and systemic immune responses. In CF, the combination of recurrent antibiotic exposure, chronic infection, and dysbiosis creates a state of persistent immune activation. Pro-inflammatory cytokines such as TNF-α and interleukin-1β can directly impair beta-cell function and induce apoptosis. Moreover, the loss of immunomodulatory bacteria like Faecalibacterium may reduce regulatory T-cell activity, allowing inflammation to go unchecked. This chronic low-grade inflammation is a key driver of insulin resistance and could accelerate the progression from normal glucose tolerance to CFRD.

Clinical Implications and Potential Therapies

The recognition that gut microbiota dysbiosis plays a role in CFRD has opened up several potential therapeutic strategies, many of which are being actively investigated.

Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. In CF, various probiotic strains have been studied for their effects on lung function, gastrointestinal symptoms, and inflammation. A few small trials have also examined metabolic outcomes. For example, a 2018 randomized controlled trial by Nikniaz et al. found that administration of Lactobacillus reuteri for 6 months improved insulin sensitivity and reduced fasting glucose in CF patients. However, larger and longer trials are needed before probiotics can be routinely recommended for CFRD prevention or management. The choice of strain, dose, and delivery method must be optimized, and safety considerations — especially in immunocompromised patients — must be addressed.

Prebiotics and Dietary Fiber

Prebiotics are nondigestible food ingredients that selectively stimulate the growth and activity of beneficial gut bacteria. Inulin-type fructans and galacto-oligosaccharides have been shown to increase Bifidobacterium and butyrate-producing species in the colon. Dietary fiber supplementation may offer a simple and safe way to increase SCFA production and improve metabolic health in CF. A 2020 pilot study by Li et al. demonstrated that daily supplementation with a prebiotic fiber blend for 8 weeks increased fecal butyrate and improved glucose tolerance in a small group of CF patients. More studies are needed to confirm these findings and to determine the optimal fiber type and dose.

Fecal Microbiota Transplantation (FMT)

FMT involves transferring stool from a healthy donor into the gut of a recipient to restore a balanced microbial community. FMT has shown remarkable efficacy for recurrent Clostridioides difficile infection and is being explored for many other conditions, including metabolic syndrome. In CF, a few small case series have reported improvements in gastrointestinal symptoms and, in some cases, modest improvements in metabolic parameters. However, the risk of transferring pathogens or unintended microbes remains a concern, especially in patients with compromised lung function. Rigorous donor screening and carefully controlled clinical trials are necessary before FMT can be considered a viable therapy for CFRD.

CFTR Modulators and the Microbiome

The advent of highly effective CFTR modulator therapies, such as the triple-combination elexacaftor/tezacaftor/ivacaftor (ETI), has revolutionized CF care. These drugs partially restore CFTR function, leading to dramatic improvements in lung function, sweat chloride, and nutritional status. Excitingly, emerging evidence suggests that CFTR modulators may also positively affect the gut microbiota. A 2022 study by Yarlagadda et al. found that after 12 months of ETI therapy, CF patients showed increased gut microbial diversity and a relative increase in butyrate-producing Firmicutes and Ruminococcus. These microbial changes correlated with improved inflammatory markers and weight gain. It is plausible that part of the metabolic benefit of ETI is mediated through restoration of a healthier gut microbiome. Further research should investigate whether combining modulators with microbiome-targeted interventions yields additive or synergistic benefit.

Personalized Microbiome-Based Approaches

Given the high inter-individual variability in gut microbiota composition and response to interventions, a one-size-fits-all approach is unlikely to succeed. The future of CFRD management may involve precision microbiome medicine: using an individual’s baseline microbial profile to predict which probiotic, prebiotic, dietary change, or even FMT donor will be most effective. Advances in sequencing technology and machine learning are making this increasingly feasible. However, large-scale longitudinal studies are needed to define predictive biomarkers and to validate treatment algorithms.

Current Research and Future Directions

The science of the gut microbiota in CFRD is still in its infancy, but the pace of discovery is accelerating. Key questions that researchers are working to answer include:

  • What is the temporal relationship between gut dysbiosis and the onset of CFRD? Does microbial disruption precede or follow hyperglycemia?
  • Which specific microbial species or metabolites are most causally related to insulin deficiency and resistance in CF?
  • Can we harness the microbiome to prevent or delay the progression from normal glucose tolerance to CFRD?
  • How do CFTR modulators and other CF-specific therapies interact with the gut microbiome to influence metabolic outcomes?

Answering these questions will require a combination of prospective cohort studies, interventional trials, and mechanistic experiments using gnotobiotic animal models. The Cystic Fibrosis Foundation has recognized the importance of this field and has funded several research initiatives aimed at understanding the microbiome’s role in CF. Collaborations between CF centers, microbiome scientists, and endocrinologists will be essential.

Additionally, there is a growing interest in using multi-omics approaches — combining metagenomics, metabolomics, proteomics, and transcriptomics — to capture a comprehensive picture of host-microbe interactions. Such integrative analyses could reveal novel biomarkers for early diagnosis of CFRD and identify new drug targets. For example, if a particular microbial metabolite is found to directly impair insulin secretion, that metabolite could be blocked or neutralized therapeutically.

Ultimately, the goal is to incorporate microbiome assessment into routine CF care and to develop safe, effective, and individualized microbiome-based therapies that complement existing treatments. Given the complexity of CF and the multiple factors driving CFRD, it is unlikely that a single microbial intervention will be a panacea. But by improving gut health — reducing inflammation, enhancing SCFA production, and restoring microbial diversity — we may be able to improve glucose metabolism, support better nutrition, and ultimately extend and improve the quality of life for people with CF.

The gut microbiota is not a passive bystander in cystic fibrosis-related diabetes; it is an active participant. The evidence linking dysbiosis to altered metabolism and inflammation is strong and growing. While the field awaits definitive clinical trials, it is already clear that clinicians caring for CF patients should pay attention to gut health as part of a comprehensive approach to preventing and managing CFRD. Optimizing nutrition, minimizing unnecessary antibiotics, and considering targeted probiotics or prebiotics when appropriate are all steps that can be taken now. As research progresses, the promise of microbiome medicine for CFRD may soon be realized.

To learn more about cystic fibrosis-related diabetes and the latest research on the gut microbiome, visit the Cystic Fibrosis Foundation's research page and review relevant studies on PubMed.